



SVF Vaccines receives Notice of Allowance in Japan for patent application covering treatment and prevention of hepatitis B and D

Stockholm, Sweden, 7 April 2026. SVF Vaccines AB (“SVF Vaccines” or the “Company”), a Swedish biotechnology company developing vaccines and immunotherapies for serious infectious diseases, today announced that the Japan Patent Office has issued a Notice of Allowance for the Company’s patent application titled Compositions and Methods for Treating and Preventing Hepatitis B and D.

The Notice of Allowance indicates that the Japanese patent authorities have approved the application and that the patent is expected to proceed to grant following completion of the formal issuance process. Japan represents a strategically important market for a treatment for hepatitis B and D, as well as an important jurisdiction for intellectual property protection in the field of infectious diseases.

The patent application covers compositions and methods related to the Company’s immunotherapeutic approach for treating hepatitis B and hepatitis D, and further strengthens SVF Vaccines’ growing intellectual property portfolio supporting the Company’s hepatitis programs, including its lead candidate SVF-001.

“This is an important milestone for SVF Vaccines and a positive step in strengthening our intellectual property position in a key market,” says Raheleh Nassaji, CEO of SVF Vaccines AB. “A strong patent portfolio is a central part of our strategy as we continue to advance our hepatitis B and D programs toward clinical development.”

For further information, please contact:

Raheleh Nassaji, Chief Executive Officer, SVF Vaccines AB
Phone: +46 (0) 76 495 12 85, e-mail: raheleh.nassaji@svfvaccines.com

John Öhd, Chairman of the Board, SVF Vaccines AB
Phone: +46 (0) 70 766 80 97, e-mail: john.ohd@karolinskadevelopment.com

About SVF Vaccines

SVF Vaccines AB is a Swedish biotechnology company developing vaccines and immunotherapies for serious infectious diseases, based on proprietary technology originating from research at Karolinska Institutet. The Company’s portfolio includes a lead program targeting chronic hepatitis D, as well as earlier-stage programs in additional high-need viral indications. SVF Vaccines aims to advance its pipeline



VACCINES

through focused clinical development and collaborations with academic and strategic partners.